AstraZeneca’s Calquence Gives Survival Benefit to Leukemia Patients in Phase 3 Trial

AstraZeneca’s Calquence (acalabrutinib) plus obinutuzumab as a first-line treatment helped 90 percent of chronic lymphocytic leukemia (CLL) patients survive for five years, according to the latest data from a late-stage study.

In the phase 3 ELEVATE-TN trial, the combination treatment demonstrated a statistically significant progression-free survival compared with chlorambucil plus obinutuzumab. It also showed longer overall survival for patients who received the combination treatment compared with those given chlorambucil combined with obinutuzumab.

Calquence also maintained efficacy and a sustained safety profile at four years for previously treated patients in the company’s ASCEND trial.

The trial results were presented at the 2022 American Society of Clinical Oncology (ASCO) annual meeting, June 4-7.